ArticleMaterials today. Bio2025
Zwitterionic chitosan-modified amorphous ZnCuAl-LDH eye drops for efficient treatment of bacterial keratitis.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Uncommon pathogen, common activity:Frontiers in public health · 2026Article
- Honokiol-loaded nanoparticles for targeted bacterial eradication and treatment of MRSA infection.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial keratitis caused by microbial invasion represents a significant cause of visual impairment characterized by corneal perforation, epithelial defect, intense pain, and conjunctival congestion. The widespread misuse of antibiotic eye drops in clinical treatment has accelerated the global rise of antibiotic-resistant infections, dimming the prospects for antibiotic therapy. In response, inorganic nanomaterial-based antibacterial eye drops have been developed for bacterial keratitis leveraging their structural controllability, composition diversity and ease of functionalization, However, they typically exert antibacterial effects with the assistance of laser, ultrasound, or X-ray irradiation that may cause irritation or damage to the human eye, or involve intricate structural modifications for antibacterial activation. Herein, we propose zwitterionic chitosan-modified defective amorphous ZnCuAl-layered double hydroxide nanosheets (ZC@a-LDH) as an antibacterial agent for bacterial keratitis treatment. ZC@a-LDH nanosheets demonstrate significantly enhanced antimicrobial efficacy compared with their defect-free counterparts, effectively suppressing bacterial proliferation at a minimum inhibitory concentration of 12 μg mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.